Document Detail

Critical role of soluble amyloid-β for early hippocampal hyperactivity in a mouse model of Alzheimer's disease.
MedLine Citation:
PMID:  22592800     Owner:  NLM     Status:  MEDLINE    
Alzheimer's disease (AD) is characterized by a progressive dysfunction of central neurons. Recent experimental evidence indicates that in the cortex, in addition to the silencing of a fraction of neurons, other neurons are hyperactive in amyloid-β (Aβ) plaque-enriched regions. However, it has remained unknown what comes first, neuronal silencing or hyperactivity, and what mechanisms might underlie the primary neuronal dysfunction. Here we examine the activity patterns of hippocampal CA1 neurons in a mouse model of AD in vivo using two-photon Ca(2+) imaging. We found that neuronal activity in the plaque-bearing CA1 region of older mice is profoundly altered. There was a marked increase in the fractions of both silent and hyperactive neurons, as previously also found in the cortex. Remarkably, in the hippocampus of young mice, we observed a selective increase in hyperactive neurons already before the formation of plaques, suggesting that soluble species of Aβ may underlie this impairment. Indeed, we found that acute treatment with the γ-secretase inhibitor LY-411575 reduces soluble Aβ levels and rescues the neuronal dysfunction. Furthermore, we demonstrate that direct application of soluble Aβ can induce neuronal hyperactivity in wild-type mice. Thus, our study identifies hippocampal hyperactivity as a very early functional impairment in AD transgenic mice and provides direct evidence that soluble Aβ is crucial for hippocampal hyperactivity.
Marc Aurel Busche; Xiaowei Chen; Horst A Henning; Julia Reichwald; Matthias Staufenbiel; Bert Sakmann; Arthur Konnerth
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't     Date:  2012-05-16
Journal Detail:
Title:  Proceedings of the National Academy of Sciences of the United States of America     Volume:  109     ISSN:  1091-6490     ISO Abbreviation:  Proc. Natl. Acad. Sci. U.S.A.     Publication Date:  2012 May 
Date Detail:
Created Date:  2012-05-30     Completed Date:  2012-08-24     Revised Date:  2013-06-25    
Medline Journal Info:
Nlm Unique ID:  7505876     Medline TA:  Proc Natl Acad Sci U S A     Country:  United States    
Other Details:
Languages:  eng     Pagination:  8740-5     Citation Subset:  IM    
Institut für Neurowissenschaften, Technische Universität München, 80802 Munich, Germany.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Age Factors
Alanine / analogs & derivatives,  pharmacology
Alzheimer Disease / metabolism,  pathology,  physiopathology*
Amyloid Precursor Protein Secretases / antagonists & inhibitors
Amyloid beta-Peptides / metabolism,  physiology*
Azepines / pharmacology
CA1 Region, Hippocampal / metabolism,  pathology,  physiopathology
Calcium / metabolism
Disease Models, Animal*
Hippocampus / metabolism,  pathology,  physiopathology*
Mice, Transgenic
Microscopy, Fluorescence, Multiphoton
Neurons / drug effects,  metabolism,  pathology
Plaque, Amyloid / metabolism,  pathology
Reg. No./Substance:
0/Amyloid beta-Peptides; 0/Azepines; 0/N2-((2S)-2-(3,5-difluorophenyl)-2-hydroxyethanoyl)-N1-((7S)-5-methyl-6-oxo-6,7-dihydro-5H-dibenzo(b,d)azepin-7-yl)-L-alaninamide; 56-41-7/Alanine; 7440-70-2/Calcium; EC 3.4.-/Amyloid Precursor Protein Secretases

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Canonical autophagy dependent on the class III phosphoinositide-3 kinase Vps34 is required for naive...
Next Document:  Development of experimental autoimmune encephalomyelitis (EAE) in mice requires vitamin D and the vi...